Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial2014 · 1,761 citations
2. 2Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.2014 · 35 citations
3. 3Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL).2014 · 25 citations
4. 4Restoring function in exhausted CD8 T cells during chronic viral infection2005 · 3,967 citations
5. 5Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab2023 · 231 citations